In Vivo Fibrosis Imaging: MicroCT and Ultrasound Guide
MicroCT, high-frequency ultrasound, and MRI for longitudinal fibrosis assessment in preclinical models. Covers HU thresholds, SWE, and 3Rs benefits.
Introduction: Beyond Endpoint Histology
Histological and biochemical approaches such as Sirius Red staining and hydroxyproline quantification remain the gold standard for evaluating fibrosis in preclinical studies. However, these methods share a fundamental limitation: they provide only a single snapshot at the study endpoint.
What was happening at Week 2 of dosing? When did the disease reach its peak?
Answering these questions with conventional approaches requires sacrificing separate cohorts at each time point, creating several downstream problems:
- Escalating animal numbers: Dedicating groups to each time point can multiply total animal usage two- to four-fold, increasing both ethical burden and cost
- Inter-animal variability: Without within-subject longitudinal data, statistical power for group comparisons drops substantially
- Missed dynamics: Transient worsening, spontaneous recovery, or non-linear disease trajectories between scheduled time points go undetected
In vivo imaging resolves these issues by enabling repeated, non-invasive scans of the same animal over time. This article provides a comprehensive guide to three major imaging modalities—MicroCT, high-frequency ultrasound, and MRI—and their application to preclinical fibrosis research.
Quick Reference: Imaging Modality Comparison
| Modality | Primary Target Organs | Spatial Resolution | Key Readouts | Scan Time | Radiation / Invasiveness |
|---|---|---|---|---|---|
| MicroCT | Lung | 10–50 µm | Aerated volume, lung density (HU), high-attenuation volume | 3–10 min | Low-dose X-ray |
| High-frequency ultrasound | Heart, liver, kidney | 30–100 µm | Cardiac function (EF, E/A ratio), tissue stiffness (SWE), blood flow | 10–30 min | Non-invasive (ultrasound) |
| MRI | Heart, liver, kidney | 50–200 µm | T1 mapping, ECV, fat fraction | 20–60 min | Non-invasive (magnetic field) |
Rule of thumb: MicroCT is the first-line modality for pulmonary fibrosis; ultrasound or MRI is preferred for soft-tissue fibrosis in the liver, kidney, and heart.
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
1. MicroCT for Pulmonary Fibrosis Assessment
1-1. Principles and Key Parameters
In preclinical models of idiopathic pulmonary fibrosis (IPF)—particularly the bleomycin-induced lung fibrosis model—MicroCT has become the definitive tool for non-invasive longitudinal evaluation.
The primary parameters quantifiable by MicroCT include:
- Aerated Lung Volume: By applying Hounsfield Unit (HU) thresholds, the software automatically segments healthy aerated regions (−900 to −300 HU) from fibrotic or inflamed high-attenuation zones (> −300 HU) and calculates their respective volumes
- Mean Lung Density: The average HU value across the entire lung field; this value increases as fibrosis progresses
- High-Density Volume Ratio: The proportion (%) of high-density regions relative to total lung volume, which normalizes for inter-animal variation in body size
1-2. Interpreting Hounsfield Units (HU)
The Hounsfield Unit is a relative scale of X-ray attenuation, defined with water at 0 HU and air at −1000 HU. The typical HU distribution in fibrotic lungs is as follows:
| Classification | HU Range | Histological Correlate |
|---|---|---|
| Normal aeration | −900 to −500 HU | Intact alveolar architecture |
| Ground-glass opacity | −500 to −300 HU | Mild inflammation, interstitial thickening |
| Consolidation / fibrosis | −300 to 0 HU | Dense fibrosis, cellular infiltration |
| Honeycombing-like changes | Mixed pattern | Cystic spaces surrounded by fibrotic tissue |
Caution: High-density areas observed during the acute phase (Day 3–7) may reflect inflammatory edema or hemorrhage rather than established fibrosis. Correlation with histology is essential for accurate temporal interpretation.
1-3. Best Practices in the Bleomycin Model
Intratracheal instillation of bleomycin (BLM) is notoriously variable in drug distribution across the lungs. The following MicroCT-guided protocol has become the current best practice:
- Baseline scan (Day −1 or Day 0): Acquire pre-BLM images to establish each animal's normal lung parameters
- Fibrosis confirmation scan (Day 7–10): Image post-BLM to verify that adequate fibrosis has developed; exclude non-responders
- Randomized group allocation: Use MicroCT-derived fibrosis severity scores to balance disease burden across treatment groups
- Therapeutic dosing initiation: Begin drug treatment against already-established fibrosis—a clinically relevant question
- Longitudinal scans (Day 14, 21): Track intra-subject changes over time
- Endpoint (Day 21–28): Euthanize and perform histological assessment
This "MicroCT-guided randomization" approach eliminates poor responders before group allocation, dramatically reducing inter-group variability. The result is improved statistical power with fewer animals.
1-4. Strengths and Limitations of MicroCT
Strengths:
- High spatial resolution (10–50 µm) detects subtle structural changes
- Automated quantitative analysis (ROI segmentation, volumetric calculations)
- Respiratory-gated acquisition minimizes motion artifacts
- Short scan times (3–10 min) impose minimal burden on animals
Limitations:
- Poor soft-tissue contrast (unsuitable for hepatic or renal fibrosis)
- Cumulative X-ray exposure (monitor total dose in long-term longitudinal studies)
- Cannot distinguish inflammation from fibrosis on HU values alone
- Limited vascular assessment without contrast agents
2. High-Frequency Ultrasound for Hepatic, Renal, and Cardiac Fibrosis
Small-animal high-frequency ultrasound platforms (e.g., VisualSonics Vevo series; 30–70 MHz) offer real-time structural and functional assessment of soft tissues.
2-1. Liver: Shear Wave Elastography (SWE)
Shear Wave Elastography (SWE) quantifies tissue stiffness (kPa) non-invasively by measuring the propagation velocity of ultrasound-induced shear waves. The principle mirrors that of clinical FibroScan (transient elastography), adapted for high-resolution small-animal imaging.
Preclinical applications:
- MASH models (AMLN diet, STAM, etc.): Longitudinal monitoring of increasing liver stiffness as fibrosis progresses. Significant stiffness elevations are typically detectable from Metavir F2–F3 equivalent stages
- CCl4 model: Tracks graded increases in stiffness with dosing duration and can quantify fibrosis regression after toxicant withdrawal
- Reference values: Normal mouse liver 2–4 kPa; mild fibrosis 5–8 kPa; advanced fibrosis 10–20 kPa (instrument- and probe-dependent)
Measurement considerations:
- Standardize the measurement site (mid-right lobe recommended; avoid portal vein and gallbladder proximity)
- Use the median of multiple measurements to minimize respiratory variability
- Control fasting status, as postprandial portal flow increases can elevate stiffness readings
2-2. Kidney: Cortical Echogenicity and Perfusion
In renal fibrosis models (UUO, 5/6 nephrectomy, adenine diet, etc.), the following ultrasound parameters are informative:
- Cortical Echogenicity: Collagen deposition and tubular atrophy in fibrotic kidneys increase cortical echo brightness. Semi-quantitative scoring via the Cortical-to-Liver Brightness Ratio uses the liver as an internal reference
- Renal dimensions (long-axis length, cortical thickness): Progressive renal atrophy in chronic fibrosis can be tracked longitudinally
- Color / Power Doppler: Capillary rarefaction accompanying renal fibrosis manifests as reduced cortical perfusion signals. Resistive Index (RI) elevation in the renal artery can also be quantified
2-3. Heart: Echocardiographic Structural and Functional Assessment
Echocardiography is indispensable in cardiac fibrosis models (TAC, angiotensin II infusion, HFpEF models, etc.).
Key parameters:
| Parameter | Significance | Normal Range (Mouse) |
|---|---|---|
| LVEF (LV ejection fraction) | Systolic function | 55–75% |
| FS (fractional shortening) | Simplified systolic function index | 30–45% |
| E/A ratio | Diastolic function | 1.2–2.0 |
| E/e' ratio | Estimate of LV filling pressure | < 20 |
| LVIDd (LV internal diameter, diastole) | LV remodeling assessment | 3.5–4.5 mm |
| IVSd (interventricular septum, diastole) | Hypertrophy assessment | 0.6–0.9 mm |
Interpreting the E/A ratio:
- E/A > 1.5: Normal relaxation pattern
- E/A < 1.0: Impaired relaxation (Grade I diastolic dysfunction) — suggestive of early myocardial fibrosis
- E/A > 2.0 (pseudonormalization): Restrictive pattern (Grade III) — indicates advanced fibrosis and stiffening
Practical note: The principal value of echocardiography lies in providing a clinically meaningful functional endpoint—whether cardiac pump function has improved—rather than directly measuring collagen content.
3. MRI-Based Approaches
MRI offers superior soft-tissue contrast and zero ionizing radiation. Several quantitative MRI techniques have been applied to preclinical fibrosis research in recent years.
3-1. T1 Mapping
T1 relaxation time reflects tissue water content and fibrotic remodeling. In myocardial fibrosis, fibrotic regions exhibit prolonged T1 values (collagen has high water content), enabling non-contrast estimation of diffuse fibrosis via Native T1 mapping.
- Native T1 mapping: Contrast-free assessment of diffuse myocardial fibrosis
- Strengths: Completely non-invasive, highly reproducible
- Limitations: Inflammation and edema also prolong T1; differentiation from fibrosis requires clinical context
3-2. Extracellular Volume Fraction (ECV)
ECV is calculated from pre- and post-gadolinium T1 values combined with hematocrit, and reflects the degree of myocardial fibrosis more accurately than Native T1 alone.
- Normal myocardium: ECV 25–30%
- Fibrotic myocardium: ECV 35–50% or higher
- Strengths: Strong correlation with histological collagen area fraction
- Limitations: Requires gadolinium contrast agent administration and hematocrit measurement
3-3. Liver and Kidney MRI
- MR Elastography (MRE): Measures tissue stiffness using the same shear-wave principle as ultrasound SWE, with the advantage of generating organ-wide stiffness maps over MRI's large field of view
- T1rho mapping: Reported to detect early fibrosis by reflecting changes in proteoglycan content associated with hepatic fibrosis
- Diffusion-Weighted Imaging (DWI): Decreased ADC (apparent diffusion coefficient) serves as an imaging biomarker for fibrosis
Cost consideration: Small-animal MRI systems are expensive to acquire and operate, and scan times are long. MRI is best suited for mechanistic studies and proof-of-concept (PoC) experiments rather than routine efficacy screening.
4. Recommended Longitudinal Study Design
Below is a recommended MicroCT-integrated study design using the bleomycin lung fibrosis model as an example.
Day -1 Baseline MicroCT scan
Day 0 Bleomycin intratracheal instillation (1.5–3.0 mg/kg)
Day 7 MicroCT scan → Fibrosis confirmation → Randomized group allocation
Day 7 Therapeutic dosing begins
Day 14 Interim MicroCT scan
Day 21 Final MicroCT scan → Euthanasia
→ Left lung: BALF collection, hydroxyproline assay
→ Right lung: Fixation, Sirius Red staining, Ashcroft scoring
Group design example (n = 8–10 per group):
- G1: Sham (saline) + Vehicle
- G2: BLM + Vehicle (negative control)
- G3: BLM + Nintedanib (positive control, 30 mg/kg BID)
- G4: BLM + Test compound (low dose)
- G5: BLM + Test compound (high dose)
Advantages of this design:
- Day 7 MicroCT-based randomization equalizes baseline fibrosis severity across groups
- Within-subject longitudinal data enable repeated-measures ANOVA, partitioning out intra-subject variability from the error term and substantially boosting statistical power
- Four time points (Day −1, Day 7, Day 14, Day 21) fully capture the temporal course of disease
- Endpoint histology and biochemistry validate imaging findings
5. Contribution to the 3Rs and Ethical Significance
The adoption of in vivo imaging directly advances the 3Rs principles—the internationally recognized framework for humane animal experimentation.
Reduction
A conventional "sacrifice-at-each-time-point" design would require 4 time points x 5 groups x n = 8 = 160 animals. A longitudinal imaging design achieves equivalent (or superior) data with 5 groups x n = 8 = 40 animals—a 75% reduction in animal usage.
Refinement
- Non-invasive monitoring eliminates interim sacrifices
- Early detection of severely affected animals facilitates timely application of humane endpoints
- Anesthesia duration is short (minutes to 30 min); with proper physiological monitoring, animal burden is minimal
Replacement
- Accumulated imaging datasets can improve the predictive accuracy of future in silico models (computational simulations)
- Direct translational comparison with human clinical imaging is possible
Regulatory agencies including the FDA and EMA increasingly support adoption of advanced assessment methods that enhance animal welfare under 3R principles and enable longitudinal evaluation, making imaging a strategically aligned option with current regulatory trends (no specific imaging modality is universally mandated by current guidance).
6. Troubleshooting
6-1. Motion Artifacts
Problem: Respiratory and cardiac motion blur degrades quantitative accuracy.
Solutions:
- Respiratory gating: Use a respiratory sensor to acquire images only during expiration; mandatory for lung MicroCT
- Cardiac gating: ECG-triggered acquisition captures specific cardiac phases in echocardiography and MRI
- Retrospective gating: Continuous acquisition followed by post hoc frame selection based on respiratory/cardiac phase data; more flexible than prospective gating but increases total scan time
6-2. Anesthetic Effects
Problem: Inhaled anesthetics such as isoflurane depress cardiac function (heart rate, blood pressure, cardiac output), confounding echocardiographic data.
Solutions:
- Maintain isoflurane at the minimum effective concentration (1.0–1.5%)
- Standardize the interval from induction to image acquisition (e.g., begin scanning 5 minutes after induction)
- Maintain body temperature at 37 +/- 0.5 degrees C using a heating pad
- Verify heart rate is within 400–500 bpm (mouse); values below this range indicate excessive anesthetic depth
6-3. Optimizing Lung MicroCT Image Quality
| Problem | Cause | Solution |
|---|---|---|
| Global blurring | Respiratory artifact | Verify gating, stabilize respiration rate |
| Streak artifacts | Metal objects (e.g., staples) | Position outside the field of view |
| Poor left-right differentiation | Insufficient tube voltage | Use 50–80 kVp with appropriate filtration |
| Value drift over serial scans | Calibration drift | Perform routine phantom-based calibration |
6-4. Improving SWE Reproducibility
- Standardize probe pressure: Excessive compression overestimates stiffness. Use a standoff pad and apply minimal contact pressure
- Measurement repetitions: Acquire at least 5 measurements per site; confirm IQR/median ratio is within 30%
- Operator variability: Ideally, a single trained operator performs all measurements throughout the study
7. The Case for a Hybrid Evaluation Strategy
It bears repeating: in vivo imaging is not a complete replacement for histology.
"High-attenuation areas" on MicroCT can arise from acute inflammatory edema and cellular infiltration just as readily as from collagen deposition. Imaging data alone cannot definitively conclude that an anti-fibrotic drug has worked.
Recommended hybrid approach:
- Screening / group allocation: Use imaging to balance baseline disease severity
- Longitudinal monitoring: Track treatment responses within the same animal (leveraging the statistical advantages of repeated-measures designs)
- Endpoint confirmation: At study termination, perform histological assessment (Sirius Red staining, Ashcroft score, etc.) and biochemical evaluation (hydroxyproline assay, etc.)
- Correlation analysis: Validate imaging parameters against endpoint histology to confirm the biological meaning of imaging readouts
This integrated approach delivers both high-temporal-resolution longitudinal data and definitive tissue-level confirmation of fibrosis.
Related Articles
- Quantitative Fibrosis Assessment: Sirius Red, Hydroxyproline, and AI-Based Analysis
- Sirius Red Staining Protocol: A Complete Guide
- Bleomycin Model Pitfalls and How to Avoid Them
- Sample Size Calculation for Preclinical Fibrosis Studies
- Hydroxyproline Assay: A Practical Guide
References
1. De Langhe E, et al. Quantification of lung fibrosis and emphysema in mice using automated micro-computed tomography. PLoS One. 2012;7(8):e43123. (PubMed)
2. Liedtke C, et al. Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair. 2013;6(1):19. (PubMed)
3. Vande Velde G, et al. Longitudinal micro-CT provides biomarkers of lung disease that can be used to assess the effect of therapy in preclinical mouse models, and reveal compensatory changes in lung volume. Dis Model Mech. 2016;9(1):91-98. (PubMed)
4. Sarvazyan AP, et al. Shear wave elasticity imaging: a new ultrasonic technology of medical diagnostics. Ultrasound Med Biol. 1998;24(9):1419-1435. (PubMed)
5. Peng H, et al. High-frequency ultrasound for assessment of hepatic steatosis and fibrosis in mice. Ultrasound Med Biol. 2019;45(12):3246-3258. (PubMed)
6. Ram R, et al. New approaches in small animal echocardiography: imaging the sounds of silence. Am J Physiol Heart Circ Physiol. 2011;301(2):H267-H279. (PubMed)
7. Messroghli DR, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR). J Cardiovasc Magn Reson. 2017;19(1):75. (PubMed)
8. Hubrecht RC, Carter E. The 3Rs and humane experimental technique: implementing change. Animals (Basel). 2019;9(10):754. (PubMed)